Senores Pharmaceuticals Limited has informed the Exchange regarding financial results for quarter and financial year ended March 31, 2026.
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Senores Pharmaceuticals reported strong audited consolidated results for FY26 with revenue from operations growing 59% to Rs. 632.63 crore from Rs. 398.25 crore in FY25. Net profit after tax increased 53% to Rs. 137.32 crore from Rs. 89.82 crore. For Q4 FY26 standalone, revenue was Rs. 36.81 crore and PAT was Rs. 8.48 crore. The company received an unmodified audit opinion confirming clean financials. Management also announced the resignation of Company Secretary Vinay Kumar Mishra effective June 10, 2026, and appointment of Sharp & Tannan Associates as internal auditor for FY27. The company completed acquisitions of Apnar Pharma (75% stake) and Zoraya Pharmaceuticals during the year.
Strong financial performance with robust revenue and profit growth reflects successful execution of expansion strategy. The clean audit opinion and improved profitability metrics are positive signals for investors. However, the upcoming resignation of the Company Secretary may create near-term compliance attention.